预约演示
更新于：2026-06-04
Chiatai Qingchunbao Pharmaceutical Co., Ltd.
更新于：2026-06-04
概览
标签
心血管疾病
神经系统疾病
其他疾病
中药
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
暂无数据
关联
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
ChiCTR2500095860
Clinical Pharmacological Evaluation of Guanxinning Tablets in the Treatment of Coronary Heart Disease with Concomitant Heart Failure
ChiCTR2400088477
A Double-Blind, Single-Center, Randomized Controlled Trial on the Influence of Guanxinning Tablets on CT Myocardial Perfusion in Patients with Coronary Heart Disease without Complete Blood Vessel Reconstruction
ChiCTR2400088437
A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial of Guanxinning tablets in the treatment of stable exertional angina (blood stasis syndrome)
100 项与 正大青春宝药业有限公司 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2026-04-27COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
The Integration of Pharmacokinetics, Cardiac Tissue Distribution, Network Pharmacology, and Experimental Verification to Reveal the Bioactive Components and Pharmacological Mechanisms of Guanxinning Tablet Against Coronary Heart Disease
Article
作者: Shen, Peiqiang ; Tao, Yi ; Wang, Yingchao ; Wang, Mulan ; Wang, Yule ; Li, Jun ; Li, Miaofu
Introduction::
Coronary heart disease (CHD) is a leading cause of morbidity and mortality worldwide,
yet therapeutic options remain limited. Guanxinning tablet (GXNT), a component-based Chinese medicine
containing Danshen and Chuanxiong, has demonstrated clinical efficacy and safety for CHD patients
with heart-blood stagnation syndrome. However, its bioactive constituents and underlying pharmacological
mechanisms remain undefined. This study aimed to identify the bioactive components of GXNT and elucidate
its anti-CHD mechanisms.
Methods::
The pharmacokinetics and cardiac distribution of five GXNT constituents were investigated using
a validated ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method.
Network pharmacology revealed pivotal targets and pathways against CHD, which were verified by molecular
docking and in vitro experiments.
Results::
A validated UPLC-MS/MS method was developed to quantify danshensu, salvianolic acid B, protocatechuic
acid, ferulic acid, and senkyunolide I in biological samples. These compounds showed promising
in vivo bioactivity, marked by rapid absorption, high systemic exposure, and efficient cardiac distribution.
The detailed network analyses linked GXNT’s efficacy to inflammation-related pathways, identifying TLR4,
NFKB1, TNF, IL6, IL1B, and AKT1 as hub targets. The docking results confirmed strong binding affinities
between five compounds and these targets. Cell experiments demonstrated that GXNT and its bioactive components
exerted cardioprotection by normalizing the overexpression of key inflammatory factors.
Discussion::
Firstly, the pharmacokinetic properties of GXNT’s bioactive components require further investigation
using a rodent disease model of CHD. Secondly, in vivo follow-up animal experiments are needed to
validate the present findings further. Thirdly, beyond inflammation-related signaling pathways, the relationship
between GXNT’s anti-CHD action and other enriched pathways (e.g., the AGE-RAGE signaling pathway
in diabetic complications, the HIF-1 signaling pathway, and the PI3K-Akt signaling pathway) warrants
further exploration.
conclusion::
CONCLUSION
In summary, a rapid, sensitive and reliable UPLC-MS/MS analytical method was successfully developed and applied to investigate the pharmacokinetics and cardiac tissue distribution of danshensu, salvianolic acid B, protocatechuic acid, ferulic acid, and senkyunolide I after intragastric administration of GXNT. The results highlighted the bioactive potential of these components in vivo. Subsequent network pharmacology, molecular docking, and experimental verification preliminarily manifested that the anti-CHD effects of GXNT and its bioactive compounds were strongly correlated to TLR4/NF-κB mediated inflammation-related pathways. These findings not only provide critical insights into the anti-CHD active constituents and molecular mechanisms of GXNT, but also offer potential bioactive markers for improving its quality control.
Conclusion::
The favorable pharmacokinetics and cardiac distribution of five GXNT constituents underscored
their bioactive potential. GXNT and its bioactive compounds exerted cardioprotective effects against
CHD, partly by regulating TLR4/NF-κB-mediated inflammation-related pathways. These findings provide
insights into the bioactive components and mechanisms of GXNT against CHD, supporting its further development
and quality control.
2025-11-01PHYTOMEDICINE
Kang Shuai Lao Pian exerts anti-aging effects by enhancing mitochondrial oxidative metabolism
Article
作者: Wang, Ziyi ; Deng, Hao ; Wang, Xiaodan ; Zhang, Kai ; Fan, Guanwei ; Chen, Feng ; Liu, Li ; Li, Lan ; Li, Tian ; Zhao, Ziran ; Ni, Jingyu
BACKGROUND:
Mitochondrial dysfunction is regarded as a central node in the network of senescence markers. Therefore, rebuilding mitochondrial function is crucial for slowing down the aging process in multiple organs. Kang Shuai Lao Pian (KSLP), a traditional herbal formula with anti-aging properties, has multiple pharmacological effects. Nevertheless, the impact of KSLP on the overall aging state and mitochondrial function has not been explored.
PURPOSE:
The purpose of this study was to uncover the effects of KSLP on the overall aging state and reveal the underlying mechanism through which KSLP exerts its effects.
METHODS:
We constructed aged mouse models to evaluate the multidimensional efficacy of KSLP. Subsequently, with the help of multi-omics joint analysis technology, we predicted the potential targets of the KSLP in modulating the aging of the heart, brain, and gastrocnemius. Finally, we employed targeted metabolomic assays, qRT-PCR, and western blot to validate the molecular mechanism underlying KSLP treatment in aging.
RESULTS:
We observed that Kang Shuai Lao Pian alleviated the aging-associated phenotypes across the heart, brain, and gastrocnemius by altering seven aging hallmarks, including mitochondrial dysfunction, deregulated nutrient-sensing, intercellular communication, etc. Notably, multi-organ integration analysis identified the Oxidative phosphorylation (OXPHOS) pathway, widely regulated by KSLP in individual tissues, as the core pathway for delaying aging. We further elucidated that KSLP resets the OXPHOS pathway and promotes pyruvate oxidation, improving the coupling of glycolysis and glucose oxidation to maintain myocardial mitochondrial oxidative metabolism.
CONCLUSIONS:
Our work highlights that KSLP promotes mitochondrial rejuvenation in aged mice by coordinately enhancing pyruvate oxidation capacity and electron transport chain (ETC) efficiency. Furthermore, we reveal the molecular landscapes by which KSLP regulates aging in diverse organs, offering a promising strategy for maintaining mitochondrial oxidative metabolism and delaying aging.
2024-05-01Journal of chromatography. A
Detection of trace components in Xiangdan injection of Dalbergia odorifera based on microextraction and back-extraction along with bar-form-diagram strategy
Article
作者: Zhang, Hui ; Yan, Jizhong ; Pan, Yingfeng ; Liu, Xiaoyi ; Pan, Yixia ; Chen, Yuan ; Zhang, Hongxu ; Yang, Yanqi
Xiangdan Injection are commonly used traditional Chinese medicine formulations for the clinical treatment of cardiovascular diseases. However, the trace components of Dalbergia odorifera in Xiangdan Injection pose a challenge for evaluating its quality due to the difficulty of detection. This study proposes a technology combining dispersive liquid-liquid microextraction and back-extraction (DLLME-BE) along with Bar-Form-Diagram (BFD) to address this issue. The proposed combination method involves vortex-mixing tetradecane, which has a lower density than water, with the sample solution to facilitate the transfer of the target components. Subsequently, a new vortex-assisted liquid-liquid extraction step is performed to enrich the components of Dalbergia odorifera in acetonitrile. The sample analysis was performed on HPLC-DAD, and a clear overview of the chemical composition was obtained by integrating spectral and chromatographic information using BFD. The combination of BFD and CRITIC-TOPSIS strategies was used to optimize the process parameters of DLLME-BE. The determined optimal sample pre-treatment process parameters were as follows: 200 μL extraction solvent, 60 s extraction time, 50 μL back-extraction solvent, and 90 s back-extraction time. Based on the above strategy, a total of 29 trace components, including trans-nerolidol, were detected in the Xiangdan Injection. This combination technology provides valuable guidance for the enrichment analysis of trace components in traditional Chinese medicines.
100 项与 正大青春宝药业有限公司 相关的药物交易
登录后查看更多信息
100 项与 正大青春宝药业有限公司 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2026年06月10日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
临床申请批准
2
1
批准上市
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用